Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Net margin
Charles River Laboratories International, Inc.'s net margin over the twelve months to 30 June 2026 was −5.96%, down 2.4 percentage points from fiscal 2025 (−3.59%). Over the past ten years it has ranged from −3.59% (fiscal 2025) to 12.5% (fiscal 2020) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of −6.37% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −3.59% | (3.84) |
| FY2024 | 0.25% | (11.24) |
| FY2023 | 11.5% | (0.74) |
| FY2022 | 12.2% | 1.19 |
| FY2021 | 11.0% | (1.42) |
| FY2020 | 12.5% | 2.85 |
| FY2019 | 9.61% | (0.38) |
| FY2018 | 9.99% | 3.35 |
| FY2017 | 6.64% | (2.56) |
| FY2016 | 9.20% | (1.75) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −0.15% | 1.34 |
| Mar 2026 | −1.49% | 26.33 |
| Dec 2025 | −27.8% | (33.24) |
| Sep 2025 | 5.42% | 0.35 |
| 42 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| QGEN QIAGEN N.V. compare | 19.5% |
| MEDP Medpace Holdings, Inc. compare | 17.7% |
| DGX Quest Diagnostics Incorporated compare | 9.15% |
| RVTY Revvity Inc. compare | 8.16% |
| LH Labcorp Holdings Inc. compare | 6.99% |
| ICLR ICON PLC compare | 0.51% |
| CRL Charles River Laboratories International, Inc. | −5.96% |
| TWST Twist Bioscience Corporation compare | −31.7% |
| GH Guardant Health, Inc. compare | −38.3% |
| Diagnostics & Research industry median | −6.37% |
| Healthcare sector median | 0.00% |
| Market median | 0.45% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement